

Press Release



Notice of Acquisition of Our Shares Held by Subsidiaries

TOKYO, April 23rd, 2021 - ASKA Pharmaceutical Co., Ltd. (Headquarters: Minato-ku, Tokyo, President: Takashi Yamaguchi, hereinafter “ASKA Pharmaceutical or Subsidiary”), a wholly owned subsidiary of ASKA Pharmaceutical Holdings Co., Ltd., announced that it resolved to pay dividends in kind to us of its shares at an extraordinary general meeting of shareholders held on April 23, 2021 (a written resolution pursuant to Article 319-1 of the Companies Act).

1. Background of Share Acquisition

We were established on April 1, 2021, as the wholly-owned parent company of ASKA Pharmaceutical through a sole share transfer. As a result of the share transfer, 2,073,600 shares of us were allotted and delivered for 2,073,600 shares of treasury shares the Subsidiary had held.

Article 135-3 of the Companies Act requires that shares of the parent company held by subsidiaries be disposed of at a considerable time. Therefore, at the extraordinary general meeting of shareholders held on April 23, 2021, we decided to pay dividends in kind on all of the shares held by the Subsidiary. Accordingly, we will repurchase 2,073,600 shares of the treasury shares on May 14, 2021.

This is not a repurchase of treasury shares pursuant to the provisions of Paragraph 1 of Article 156 as applied by replacing certain terms pursuant to the provisions of Article 163 of the Companies Act.

2. Matters Concerning the Share Acquisition of the Subsidiary

Name of the Subsidiary	ASKA Pharmaceutical Co., Ltd.
Address	5-1, Shibaura 2-chome, Minato-ku, Tokyo
Class of Share	Common shares
Number of the Share Acquisition	2,073,600 shares
(Ratio to the total number of issued shares)	6.78%
Method of the Share Acquisition	Acquisition by dividends-in-kind
Scheduled Date of the Share Acquisition	May 14, 2021
(Reference) Status of treasury share holdings as of April 1, 2021	
Total number of issued shares	30,563,199 shares
Number of treasury shares	0

【Contact】

Corporate Planning Department, ASKA Pharmaceutical Holdings Co., Ltd.
TEL: +81-3-5484-8366